The Goldman Sachs Group set a €46.00 ($54.12) price target on Fresenius SE & Co. KGaA (FRA:FRE) in a report issued on Monday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
FRE has been the subject of several other reports. Credit Suisse Group set a €40.00 ($47.06) target price on shares of Fresenius SE & Co. KGaA and gave the stock a neutral rating in a research report on Monday, May 10th. Independent Research set a €47.00 ($55.29) price target on Fresenius SE & Co. KGaA and gave the company a buy rating in a report on Wednesday, February 24th. JPMorgan Chase & Co. set a €50.00 ($58.82) price objective on shares of Fresenius SE & Co. KGaA and gave the stock a buy rating in a research note on Thursday, May 20th. Nord/LB set a €52.00 ($61.18) price target on Fresenius SE & Co. KGaA and gave the stock a buy rating in a report on Tuesday, May 11th. Finally, Sanford C. Bernstein set a €41.00 ($48.24) price objective on shares of Fresenius SE & Co. KGaA and gave the stock a buy rating in a report on Wednesday, March 17th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of €47.07 ($55.37).
Shares of Fresenius SE & Co. KGaA stock opened at €45.27 ($53.26) on Monday. Fresenius SE & Co. KGaA has a 1-year low of €60.16 ($70.78) and a 1-year high of €80.00 ($94.12). The stock’s 50 day moving average price is €41.89.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Recommended Story: What is a Market Correction?
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.